Home / Companies / Zentalis Pharmaceuticals, Inc. / 17 Jun 2025
Zentalis Pharmaceuticals, Inc.: meeting of 17 Jun 2025
Votes reported on Form N-PX, item by item
179 Form N-PX filers reported votes at the Zentalis Pharmaceuticals, Inc. meeting of 17 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 53.3% of reported votes for; 52 filers withheld from or voted against at least one nominee.
351 vote records from 69 filers. 39 of the 69 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
248 vote records from 179 filers. 135 of the 172 filers that marked the item either way voted against management. 7 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
117 vote records from 69 filers. 1 of the 69 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | Against * | For |
| Fidelity | For | Against * | For |
| Dimensional | No report | Against * | No report |
| State Street and SPDR | For | For | For |
| Invesco | For | Against * | For |
| Equitable | For | Against * | For |
| Charles Schwab | Abstain or withhold * | Against * | For |
| Nuveen and TIAA | Abstain or withhold * | Against * | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | Abstain or withhold * | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | Abstain or withhold * | Against * | For |
| PGIM and Prudential | No report | Against * | No report |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | For | For | For |
| SEI | For | Against * | For |
| T. Rowe Price | For | Against * | For |
| Thrivent | Abstain or withhold * | Against * | For |
| Lincoln Financial | For | For | For |
| Voya | Abstain or withhold * | Against * | For |
| First Trust | No report | Against * | No report |
| Russell Investments | For | Against * | For |
| Nationwide | Abstain or withhold * | Against * | For |
| Victory Capital | Abstain or withhold * | Against * | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| BNY Mellon | No report | Against * | No report |
| Principal | No report | Against * | No report |
| Pacific Life funds | For | Against * | For |
| Global X | For | Against * | For |
| Federated Hermes | Abstain or withhold * | Against * | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | Abstain or withhold * | Against * | For |
| Neuberger Berman | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Zentalis Pharmaceuticals, Inc. meeting?
179 Form N-PX filers reported votes at the meeting of 17 Jun 2025. On say-on-pay, 135 of 172 voted against management (78.5%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Zentalis Pharmaceuticals, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Zentalis Pharmaceuticals, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Zentalis Pharmaceuticals, Inc. with a meeting date within three days of 17 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.